Depersonalization disorder: pharmacological approaches

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depersonalization disorder (DPD) affects 0.8-2% of the population, causing chronic distress.
• Neurobiological studies indicate suppressed limbic activation to emotional stimuli in DPD patients.
• A proposed model links DPD to a chronic, dysfunctional anxiety-triggered inhibitory response to threat.

Purpose of the Study:

• To review current understanding and emerging treatments for Depersonalization Disorder.
• To evaluate the efficacy of novel pharmacological interventions for DPD.
• To discuss the neurobiological underpinnings of DPD in relation to stress response systems.

Main Methods:

• Literature review of neurobiological and pharmacological studies on DPD.
• Analysis of findings related to opioid receptor antagonists (naltrexone, naloxone).
• Evaluation of lamotrigine and clonazepam as potential treatments, particularly in combination with SSRIs.

Main Results:

• Conventional medications like antidepressants and antipsychotics have limited efficacy in DPD.
• Opioid receptor antagonists show potential benefit in a subgroup of DPD patients.
• Lamotrigine as an add-on treatment with SSRIs and clonazepam with SSRIs appear beneficial for specific patient groups.

Conclusions:

• DPD treatment remains challenging, with no definitive therapy currently established.
• Emerging pharmacological approaches, including opioid antagonists and specific add-on therapies, offer new avenues for DPD management.
• Understanding the stress-related neurobiology of DPD is crucial for developing effective treatments.